Clinical Trial: Treatment of Epiretinal Membranes With Ranibizumab
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Prospective Pilot Study of Lucentis for Epiretinal Membranes: the LERM Study
Brief Summary: The purpose of this study is to determine whether intraocular injection of ranibizumab decreases the retinal thickness in patients with epiretinal membranes and reduces associated symptoms.
Detailed Summary:
Sponsor: Queen's University
Current Primary Outcome: Evidence of improvement measured by optical coherence tomography [ Time Frame: 3 and 6 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Distance visual acuity (ETDRS) [ Time Frame: 3 and 6 months ]
- Near visual acuity (Snellen) [ Time Frame: 3 and 6 months ]
- Subjective change in symptoms [ Time Frame: 3 and 6 months ]
- Amsler grid improvement [ Time Frame: 3 and 6 months ]
- Quality of life improvement [ Time Frame: 6 months ]
Original Secondary Outcome: Same as current
Information By: Queen's University
Dates:
Date Received: November 9, 2010
Date Started: November 2010
Date Completion:
Last Updated: January 12, 2016
Last Verified: January 2016